Myelofibrosis Drug Pipeline Analysis Report 2025

Primary myelofibrosis has an annual incidence of 0.5-1.5 cases per 100,000 individuals in the United States. This annual range shifts to 0.1 to 1 case per 100,000 individuals in Europe. Adults aged 50 years or above are more prone to developing the condition. As a result, finding effective treatment alternatives is a key area of interest amongst the leading institutes and healthcare companies.

Report Coverage

The Myelofibrosis Drug Pipeline Insight Report by the publisher gives comprehensive insights into myelofibrosis clinical trials. It covers various aspects related to the details of each of these drugs under development for Myelofibrosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The myelofibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from myelofibrosis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing myelofibrosis product development activities related to myelofibrosis.

Myelofibrosis Drug Pipeline Outlook

Myelofibrosis is a rare blood disorder that scars the bone marrow tissue and results in disruption the production of blood cells in the body. Enlarged spleen is one of the major repercussions of the disease. It also reduces the platelet quantity, posing a risk of bleeding. Myelofibrosis can be categorised into primary and secondary. Primary myelofibrosis happens on its own while secondary myelofibrosis is associated with other bone marrow disorders. It is diagnosed via physical exams, bone marrow examinations, blood tests and others.

Treatments depend on the symptoms. For managing anemia, blood transfusions, along with Thalidomide and related drugs are advised, whereas targeted drug therapies, chemotherapy and splenectomy (surgical removal of the spleen) are advised for treating an enlarged spleen. With the increasing use of technologies such as artificial intelligence and machine learning in drug designing and development, the drug pipeline for myelofibrosis is promising and has multiple potent candidates.

Myelofibrosis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Myelofibrosis drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The myelofibrosis therapeutic assessment report covers 50+ drug analyses based on drug classes:

• JAK Inhibitors
• Immunomodulatory Drugs (IMiDs)
• Androgens
• Erythropoiesis-Stimulating Agents (ESAs)

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Myelofibrosis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for myelofibrosis. There are around 277 drugs in phase II of myelofibrosis drugs.

Myelofibrosis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under myelofibrosis pipeline analysis include JAK inhibitors, immunomodulatory drugs (IMiDs), androgens, and erythropoiesis-stimulating agents (ESAs). The choice of treatment depends on multiple factors including severity of the disease, patient profile and response to medications.

Myelofibrosis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the myelofibrosis drug insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in myelofibrosis clinical trials:

• Celgene
• GlaxoSmithKline
• Novartis Pharmaceuticals
• Bristol-Myers Squibb
• AbbVie
• Incyte Corporation
• Sanofi
• Merck Sharp & Dohme LLC
• Hoffmann-La Roche
• Takeda

Myelofibrosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for myelofibrosis . It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of myelofibrosis drug candidates.

INC424

Sponsored by Novartis Pharmaceuticals, INC424 is in Phase 3 of an open label, multicenter study with over 2000 enrolled participants. The drug is under evaluation for its safety against treating primary myelofibrosis, post polycythemia myelofibrosis or post-essential thrombocythemia myelofibrosis in patients who have received prior treatment with available medications.

Pomalidomide (CC-4047)

This drug is under investigation to treat patients with myelofibrosis with myeloid metaplasia (MMM). It is in Phase 2 of a prospective, randomized, multicenter, double-blind, active-control, parallel-group study sponsored by Celgene.

9-ING-41

The myelofibrosis drug candidate 9-ING-41 is in a Phase 2 study to evaluate its anti-cancer clinical activity against treating advanced myelofibrosis. Developed by Actuate Therapeutics Inc., it is an intravenous maleimide-based, small molecule, potent selective GSK-3ß inhibitor that is being studied in over 90 patients.

PIM447

Currently, in Phase 1 of a multi-center, open-label, dose-escalation study, PIM447 is under investigation to be used as a combination therapy with Ruxolitinib and LEE011. Each regimen will be examined for its safety, efficacy, tolerability, pharmacodynamic effects, as well as spleen activity.

Reasons To Buy This Report

The Myelofibrosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for myelofibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into myelofibrosis collaborations, regulatory environments, and potential growth opportunities within myelofibrosis pipeline insights.

Key Questions Answered in the Myelofibrosis - Pipeline Insight Report

• Which companies/institutions are leading the myelofibrosis drug development?
• What is the efficacy and safety profile of myelofibrosis pipeline drugs?
• Which company is leading the myelofibrosis pipeline development activities?
• What is the current myelofibrosis commercial assessment?
• What are the opportunities and challenges present in the myelofibrosis drug pipeline landscape?
• What is the efficacy and safety profile of myelofibrosis pipeline drugs?
• Which company is conducting major trials for myelofibrosis drugs?
• Which companies/institutions are involved in myelofibrosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in myelofibrosis?

This product will be delivered within 3-5 business days.